Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 5
1947 8
1948 5
1949 5
1957 1
1958 2
1959 1
1961 3
1962 8
1963 40
1964 27
1965 49
1966 29
1967 27
1968 58
1969 48
1970 67
1971 61
1972 69
1973 79
1974 49
1975 48
1976 43
1977 58
1978 75
1979 47
1980 57
1981 68
1982 60
1983 79
1984 98
1985 72
1986 34
1987 30
1988 40
1989 48
1990 65
1991 65
1992 86
1993 99
1994 81
1995 80
1996 83
1997 106
1998 101
1999 98
2000 111
2001 118
2002 139
2003 196
2004 236
2005 343
2006 435
2007 540
2008 602
2009 685
2010 760
2011 784
2012 935
2013 924
2014 906
2015 483
2016 330
2017 329
2018 334
2019 204
2020 14
Text availability
Article attribute
Article type
Publication date

Search Results

10,681 results
Results by year
Filters applied: . Clear all
Page 1
Targeting ATR in cancer.
Lecona E, Fernandez-Capetillo O. Lecona E, et al. Nat Rev Cancer. 2018 Sep;18(9):586-595. doi: 10.1038/s41568-018-0034-3. Nat Rev Cancer. 2018. PMID: 29899559 Review.
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J; HOPE Trial Investigators. Vichinsky E, et al. N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14. N Engl J Med. 2019. PMID: 31199090 Clinical Trial.
Availability of FLT3 inhibitors: how do we use them?
Perl AE. Perl AE. Blood. 2019 Aug 29;134(9):741-745. doi: 10.1182/blood.2019876821. Epub 2019 Jun 26. Blood. 2019. PMID: 31243041 Review.
SLFN11 Blocks Stressed Replication Forks Independently of ATR.
Murai J, Tang SW, Leo E, Baechler SA, Redon CE, Zhang H, Al Abo M, Rajapakse VN, Nakamura E, Jenkins LMM, Aladjem MI, Pommier Y. Murai J, et al. Mol Cell. 2018 Feb 1;69(3):371-384.e6. doi: 10.1016/j.molcel.2018.01.012. Mol Cell. 2018. PMID: 29395061 Free PMC article.
A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.
Yan HHN, Siu HC, Law S, Ho SL, Yue SSK, Tsui WY, Chan D, Chan AS, Ma S, Lam KO, Bartfeld S, Man AHY, Lee BCH, Chan ASY, Wong JWH, Cheng PSW, Chan AKW, Zhang J, Shi J, Fan X, Kwong DLW, Mak TW, Yuen ST, Clevers H, Leung SY. Yan HHN, et al. Cell Stem Cell. 2018 Dec 6;23(6):882-897.e11. doi: 10.1016/j.stem.2018.09.016. Epub 2018 Oct 18. Cell Stem Cell. 2018. PMID: 30344100 Free article.
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D'Andrea AD. Hill SJ, et al. Cancer Discov. 2018 Nov;8(11):1404-1421. doi: 10.1158/2159-8290.CD-18-0474. Epub 2018 Sep 13. Cancer Discov. 2018. PMID: 30213835 Free PMC article.
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Perl AE, et al. N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688. N Engl J Med. 2019. PMID: 31665578 Clinical Trial.
Acalabrutinib for mantle cell lymphoma.
Witzig TE, Inwards D. Witzig TE, et al. Blood. 2019 Jun 13;133(24):2570-2574. doi: 10.1182/blood.2019852368. Epub 2019 Apr 9. Blood. 2019. PMID: 30967367 Review.
10,681 results
Jump to page
Feedback